Linvoseltamab: primera aprobación
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|August 29, 2025
Resumen
Linvoseltamab, un anticuerpo bispecífico dirigido a BCMA y CD3, ha obtenido la aprobación de la UE para el tratamiento del mieloma múltiple recidivante / refractario. Esto marca un hito significativo en el avance de las terapias con células T para los cánceres de sangre avanzados.
Área de la Ciencia:
- En el campo de la oncología
- Inmunología
- Farmacología
Sus antecedentes:
- El mieloma múltiple es una neoplasia hematológica caracterizada por la proliferación incontrolada de células plasmáticas.
- El mieloma múltiple recidivante / refractario presenta una necesidad médica no satisfecha significativa, que a menudo requiere nuevas estrategias terapéuticas.
- El antígeno de maduración de células B (BCMA) es un objetivo validado en el mieloma múltiple.
Objetivo del estudio:
- Para resumir los hitos clave del desarrollo de linvoseltamab.
- Para resaltar la aprobación reglamentaria del linvoseltamab en la Unión Europea.
- Proporcionar una visión general del mecanismo de acción de linvoseltamab y su indicación.
Principales métodos:
- Linvoseltamab es un anticuerpo bispecífico diseñado para unirse tanto al BCMA en las células B malignas como al CD3 en las células T.
- Esta doble unión redirige a las células T para que se involucren y eliminen las células tumorales que expresan BCMA.
- Los hitos del desarrollo incluyen estudios preclínicos, ensayos clínicos y presentaciones regulatorias.
Principales resultados:
- Linvoseltamab recibió su primera autorización de comercialización en la UE el 28 de abril de 2025.
- La aprobación es para el uso en monoterapia en pacientes adultos con mieloma múltiple recidivante o refractario.
- Los pacientes deben haber recibido al menos tres terapias previas, incluidas clases específicas de agentes, y mostrar progresión de la enfermedad.
Conclusiones:
- Linvoseltamab representa una nueva opción terapéutica para los pacientes con mieloma múltiple fuertemente pretratado.
- La aprobación de la UE significa un gran avance en la inmunoterapia dirigida por BCMA.
- Este hito subraya el potencial de los anticuerpos bispecíficos en el tratamiento de tumores malignos hematológicos.
Videos de Conceptos Relacionados
01:02Prescription, Nonprescription and Orphan Drugs
842
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
842
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
223
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
223
01:26Drug Administration and Therapy Phases: Overview
738
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
738
01:19Pharmacovigilance
983
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
983